{"transactions":[{"id":704313,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance-Based Stock Option (right to buy)","published_at":"2026-07-23T20:15:05.000Z","date":"2026-07-21","kind":"grant","planned":false,"acquired":true,"shares":398018,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a performance-based stock option that becomes exercisable, if at all, on the later of (i) the first date on which the average closing price of the Issuer's common stock on the Nasdaq Stock Market over any 30 consecutive calendar-day period equals or exceeds $70.00 (the \"Stock Price Hurdle\") and (ii) the first anniversary of the date of grant, in each case subject to the Reporting Person's continued service with the Issuer as of each such date. If the Stock Price Hurdle is not achieved by the fourth anniversary of the date of grant (the \"Performance Period\"), the option will be forfeited in its entirety."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In the event of a Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer prior to the end of the Performance Period, the Stock Price Hurdle will be deemed achieved if the per-share consideration payable in the transaction equals or exceeds $70.00 (subject to equitable adjustment). If so deemed achieved, the option will vest in full immediately prior to the consummation of the Change in Control, subject to the Reporting Person's continued service with the Issuer through such time. If the Stock Price Hurdle is not achieved or deemed achieved in connection with the Change in Control, the option will be forfeited in its entirety."}],"balance_after":398018,"derivative":{"exercise_price":28.37,"expiration_date":"2036-07-20","underlying":"Common Stock","underlying_shares":398018},"source":{"system":"sec-edgar","filing":"0002111813-26-000012","document":"form4-07232026_040701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000012/form4-07232026_040701.xml","form_type":"4"}},{"id":728201,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-24T22:55:32.000Z","date":"2026-06-22","kind":"exercise","planned":false,"acquired":false,"shares":8213,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Beginning August 1, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments."}],"balance_after":4107,"derivative":{"exercise_price":1.16,"expiration_date":"2032-09-14","underlying":"Common Stock","underlying_shares":8213},"source":{"system":"sec-edgar","filing":"0002111813-26-000010","document":"form4-06242026_100628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000010/form4-06242026_100628.xml","form_type":"4"}},{"id":728200,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-24T22:55:32.000Z","date":"2026-06-22","kind":"exercise","planned":false,"acquired":false,"shares":45252,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Beginning on March 1, 2026, 12,258 shares vest monthly through January 1, 2027, with the balance fully vesting on February 1, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Form 4/A filed on June 16, 2026 (the \"Form 4/A\") contained a clerical error with respect to the expiration date of the reported security. This Form 4 corrects that clerical error to report the expiration date of the reported security as December 1, 2035. All other information reported on the Form 4/A remains unchanged."}],"balance_after":91632,"derivative":{"exercise_price":1.16,"expiration_date":"2035-12-01","underlying":"Common Stock","underlying_shares":45252},"source":{"system":"sec-edgar","filing":"0002111813-26-000010","document":"form4-06242026_100628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000010/form4-06242026_100628.xml","form_type":"4"}},{"id":728199,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-24T22:55:32.000Z","date":"2026-06-22","kind":"exercise","planned":false,"acquired":true,"shares":8213,"price":1.16,"value":9527.08,"ownership":{"direct":true},"balance_after":817699,"source":{"system":"sec-edgar","filing":"0002111813-26-000010","document":"form4-06242026_100628.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000010/form4-06242026_100628.xml","form_type":"4"}},{"id":728198,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-24T22:55:32.000Z","date":"2026-06-22","kind":"exercise","planned":false,"acquired":true,"shares":45252,"price":1.16,"value":52492.32,"ownership":{"direct":true},"balance_after":809486,"source":{"system":"sec-edgar","filing":"0002111813-26-000010","document":"form4-06242026_100628.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000010/form4-06242026_100628.xml","form_type":"4"}},{"id":728197,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-24T22:55:32.000Z","date":"2026-06-22","kind":"purchase","planned":false,"acquired":true,"shares":2806,"price":19.76,"value":55446.56,"ownership":{"direct":true},"balance_after":764234,"source":{"system":"sec-edgar","filing":"0002111813-26-000010","document":"form4-06242026_100628.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000010/form4-06242026_100628.xml","form_type":"4"}},{"id":737013,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Series B Preferred Stock","published_at":"2026-06-16T20:38:38.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":false,"shares":761.428,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub,\nLLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive 761.428 shares of the Issuer's Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub,\nLLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive 761.428 shares of the Issuer's Series B Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub,\nLLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive 761.428 shares of the Issuer's Series B Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub,\nLLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive 761.428 shares of the Issuer's Series B Preferred Stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":761428},"source":{"system":"sec-edgar","filing":"0002111813-26-000009","document":"form4-06162026_080634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000009/form4-06162026_080634.xml","form_type":"4"}},{"id":737012,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-16T20:38:38.000Z","date":"2026-06-15","kind":"exercise","planned":false,"acquired":true,"shares":761428,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to February 17, 2026 Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Sapphire Second Merger Sub,\nLLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\"), Faeth Holdings Therapeutics, Inc. (\"HoldCo\") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive 761.428 shares of the Issuer's Series B Preferred Stock."}],"balance_after":761428,"source":{"system":"sec-edgar","filing":"0002111813-26-000009","document":"form4-06162026_080634.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000009/form4-06162026_080634.xml","form_type":"4"}},{"id":737007,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-16T20:16:39.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":136884,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Received in exchange for stock options to acquire an aggregate of 686,733 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for stock options to acquire an aggregate of 686,733 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Beginning on March 1, 2026, 12,258 shares vest monthly through January 1, 2027, with the balance fully vesting on February 1, 2027."}],"balance_after":136884,"derivative":{"exercise_price":1.16,"expiration_date":"2025-11-30","underlying":"Common Stock","underlying_shares":136884},"source":{"system":"sec-edgar","filing":"0002111813-26-000008","document":"form4a-06162026_080634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000008/form4a-06162026_080634.xml","form_type":"4/A","original_submission_date":"2026-02-19"}},{"id":737006,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-16T20:16:39.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":12320,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Received in exchange for a stock option to acquire an aggregate 61,809 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for a stock option to acquire an aggregate 61,809 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Beginning August 1, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments."}],"balance_after":12320,"derivative":{"exercise_price":1.16,"expiration_date":"2032-09-14","underlying":"Common Stock","underlying_shares":12320},"source":{"system":"sec-edgar","filing":"0002111813-26-000008","document":"form4a-06162026_080634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000008/form4a-06162026_080634.xml","form_type":"4/A","original_submission_date":"2026-02-19"}},{"id":737005,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Series B Preferred Stock","published_at":"2026-06-16T20:16:39.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":761.428,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Non-Voting Convertible Preferred Stock (the \"Series B Preferred Stock\") is convertible into 1,000 shares of Common Stock of Sensei Biotherapeutics, Inc. (the \"Company\"). The Preferred Stock has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Received in exchange for 4,062,777 shares of common stock of Faeth Holdings Therapeutics, Inc. (\"HoldCo\") pursuant to an Agreement and Plan of Merger, dated February 17, 2026 (the \"Merger Agreement\"), by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (\"First Merger Sub\"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (\"Second Merger Sub\"), HoldCo and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Under the terms of the Merger Agreement, on February 17, 2026, First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the \"Merger\"). Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Company's Series B Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Company's Common Stock (\"Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 4,062,777 shares of common stock of Faeth Holdings Therapeutics, Inc. (\"HoldCo\") pursuant to an Agreement and Plan of Merger, dated February 17, 2026 (the \"Merger Agreement\"), by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (\"First Merger Sub\"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (\"Second Merger Sub\"), HoldCo and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on February 17, 2026, First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the \"Merger\"). Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Company's Series B Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Company's Common Stock (\"Common Stock\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Non-Voting Convertible Preferred Stock (the \"Series B Preferred Stock\") is convertible into 1,000 shares of Common Stock of Sensei Biotherapeutics, Inc. (the \"Company\"). The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Non-Voting Convertible Preferred Stock (the \"Series B Preferred Stock\") is convertible into 1,000 shares of Common Stock of Sensei Biotherapeutics, Inc. (the \"Company\"). The Preferred Stock has no expiration date."}],"balance_after":761428,"derivative":{"underlying":"Common Stock","underlying_shares":761428},"source":{"system":"sec-edgar","filing":"0002111813-26-000008","document":"form4a-06162026_080634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000008/form4a-06162026_080634.xml","form_type":"4/A","original_submission_date":"2026-02-19"}},{"id":894786,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-20T02:45:04.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":1239305,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares shall vest on February 19, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":1239305,"derivative":{"exercise_price":27.22,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":1239305},"source":{"system":"sec-edgar","filing":"0002111813-26-000004","document":"form4-02202026_020201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000004/form4-02202026_020201.xml","form_type":"4"}},{"id":894785,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-20T02:45:04.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":56673,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Received in exchange for stock options to acquire an aggregate of 284,320 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for stock options to acquire an aggregate of 284,320 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Immediately exercisable."}],"balance_after":56673,"derivative":{"exercise_price":1.16,"expiration_date":"2032-09-14","underlying":"Common Stock","underlying_shares":56673},"source":{"system":"sec-edgar","filing":"0002111813-26-000004","document":"form4-02202026_020201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000004/form4-02202026_020201.xml","form_type":"4"}},{"id":894784,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-20T02:45:04.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":92533,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Received in exchange for a stock option to acquire 464,222 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for a stock option to acquire 464,222 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Beginning August 1, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments."}],"balance_after":92533,"derivative":{"exercise_price":1.16,"expiration_date":"2032-09-14","underlying":"Common Stock","underlying_shares":92533},"source":{"system":"sec-edgar","filing":"0002111813-26-000004","document":"form4-02202026_020201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000004/form4-02202026_020201.xml","form_type":"4"}},{"id":894783,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":29076,"kind":"person","name":"Parikh Anand Kiran","position":1,"cik":"0002111813","reported_name":"Parikh Anand Kiran","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series B Preferred Stock","published_at":"2026-02-20T02:45:04.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":809822,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Non-Voting Convertible Preferred Stock (the \"Series B Preferred Stock\") is convertible into 1,000 shares of Common Stock of Sensei Biotherapeutics, Inc. (the \"Company\"). The Preferred Stock has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Received in exchange for 4,062,777 shares of common stock of Faeth Holdings Therapeutics, Inc. (\"HoldCo\") pursuant to an Agreement and Plan of Merger, dated February 17, 2026 (the \"Merger Agreement\"), by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (\"First Merger Sub\"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (\"Second Merger Sub\"), HoldCo and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Under the terms of the Merger Agreement, on February 17, 2026, First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the \"Merger\"). Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Company's Series B Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Company's Common Stock (\"Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 4,062,777 shares of common stock of Faeth Holdings Therapeutics, Inc. (\"HoldCo\") pursuant to an Agreement and Plan of Merger, dated February 17, 2026 (the \"Merger Agreement\"), by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (\"First Merger Sub\"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (\"Second Merger Sub\"), HoldCo and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo (\"Faeth\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Under the terms of the Merger Agreement, on February 17, 2026, First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the \"Merger\"). Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Company's Series B Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Company's Common Stock (\"Common Stock\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Non-Voting Convertible Preferred Stock (the \"Series B Preferred Stock\") is convertible into 1,000 shares of Common Stock of Sensei Biotherapeutics, Inc. (the \"Company\"). The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Non-Voting Convertible Preferred Stock (the \"Series B Preferred Stock\") is convertible into 1,000 shares of Common Stock of Sensei Biotherapeutics, Inc. (the \"Company\"). The Preferred Stock has no expiration date."}],"balance_after":809822,"derivative":{"underlying":"Common Stock","underlying_shares":809.822},"source":{"system":"sec-edgar","filing":"0002111813-26-000004","document":"form4-02202026_020201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000211181326000004/form4-02202026_020201.xml","form_type":"4"}}]}